Roth Capital Reiterates Buy on Annovis Bio, Lowers Price Target to $3
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.
Roth Capital analyst Boobalan Pachaiyappan reiterates Annovis Bio (NYSE:ANVS) with a Buy and lowers the price target from $7 to $3.
